Jeffrey M Statland

List of Publications by Year
in descending order

89	2,735	172457 29	206112 48
papers	citations	h-index	g-index

90	90	90	2823
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mexiletine for Symptoms and Signs of Myotonia in Nondystrophic Myotonia. JAMA - Journal of the American Medical Association, 2012, 308, 1357.	7.4	208
2	Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle and Nerve, 2018, 57, 522-530.	2.2	157
3	Primary lateral sclerosis. Muscle and Nerve, 2007, 35, 291-302.	2.2	134
4	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.1	119
5	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	1.9	118
6	Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurology: Clinical Practice, 2018, 8, 507-520.	1.6	115
7	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
8	Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine, 2016, 8, 331ra41.	12.4	99
9	Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - Journal of the American Medical Association, 2018, 320, 2344.	7.4	81
10	Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 735-748.	1.8	78
11	Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain, 2013, 136, 2189-2200.	7.6	77
12	Risk of functional impairment in Facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2014, 49, 520-527.	2.2	76
13	Coats syndrome in facioscapulohumeral dystrophy type 1. Neurology, 2013, 80, 1247-1250.	1.1	63
14	The diagnosis and treatment of myotonic disorders. Muscle and Nerve, 2013, 47, 632-648.	2.2	61
15	Facioscapulohumeral Muscular Dystrophy. Neurologic Clinics, 2014, 32, 721-728.	1.8	61
16	Facioscapulohumeral Muscular Dystrophy. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 1916-1931.	0.8	55
17	Primary Lateral Sclerosis. Neurologic Clinics, 2015, 33, 749-760.	1.8	53
18	Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle and Nerve, 2020, 62, 430-444.	2.2	53

#	Article	IF	Citations
19	Facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2011, 24, 423-428.	3.6	50
20	Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies. Muscle and Nerve, 2015, 52, 521-526.	2.2	50
21	Milder phenotype in facioscapulohumeral dystrophy with 7â€“10 residual D4Z4 repeats. Neurology, 2015, 85, 2147-2150.	1.1	44
22	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
23	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
24	Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2013, 23, 306-312.	0.6	41
25	Multiplex Screen of Serum Biomarkers in Facioscapulohumeral Muscular Dystrophy. Journal of Neuromuscular Diseases, 2014, 1, 181-190.	2.6	38
26	Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Human Molecular Genetics, 2020, 29, 1030-1043.	2.9	38
27	Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2017, 55, 333-337.	2.2	37
28	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35
29	Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic) Tj ETQq1 1 0.784314 rgBT /Overlock	1.8	30
30	Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy. Neurology, 2019, 92, e378-e385.	1.1	30
31	Myasthenia gravis. Neurology: Clinical Practice, 2013, 3, 126-133.	1.6	29
32	Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurology, 2019, 19, 224.	1.8	28
33	Immunohistochemical Characterization ofÂFacioscapulohumeralMuscular DystrophyÂMuscle Biopsies. Journal of Neuromuscular Diseases, 2015, 2, 291-299.	2.6	26
34	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 345-352.	1.7	26
35	Effects of weakness of orofacial muscles on swallowing and communication in FSHD. Neurology, 2019, 92, e957-e963.	1.1	25
36	An interactive voice response diary for patients with nonâ€dystrophic myotonia. Muscle and Nerve, 2011, 44, 30-35.	2.2	24

#	Article	IF	Citations
37	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcotâ€“Marieâ€“Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	2.7	23
38	Electrical impedance myography in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2016, 54, 696-701.	2.2	21
39	Facioscapulohumeral muscular dystrophy functional composite outcome measure. Muscle and Nerve, 2018, 58, 72-78.	2.2	21
40	Motor Neuron Firing Dysfunction in Spastic Patients With Primary Lateral Sclerosis. Journal of Neurophysiology, 2005, 94, 919-927.	1.8	19
41	Muscle Channelopathies. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1598-1614.	0.8	19
42	A quantitative measure of handgrip myotonia in nonâ€dystrophic myotonia. Muscle and Nerve, 2012, 46, 482-489.	2.2	17
43	Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurology, 2015, 15, 43.	1.8	17
44	Muscle Channelopathies. Neurologic Clinics, 2014, 32, 801-815.	1.8	15
45	Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1â€year followâ€up study. Muscle and Nerve, 2018, 58, 213-218.	2.2	15
46	Limbâ€girdle muscular dystrophy: A perspective from adult patients on what matters most. Muscle and Nerve, 2019, 60, 419-424.	2.2	15
47	An instrumented timed up and go in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2018, 57, 503-506.	2.2	13
48	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Journal of Neuromuscular Diseases, 2021, 8, 769-784.	2.6	13
49	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	6.9	13
50	The clinical spectrum of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 3-10.	1.7	11
51	Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2020, 61, 644-649.	2.2	10
52	Elevated plasma complement components in facioscapulohumeral dystrophy. Human Molecular Genetics, 2022, 31, 1821-1829.	2.9	10
53	Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology, 2022, 98, .	1.1	10
54	Using automated electronic medical record data extraction to model ALS survival and progression. BMC Neurology, 2018, 18, 205.	1.8	9

#	Article	IF	Citations
55	Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy. Brain, 2021, 144, 3451-3460.	7.6	9
56	The facioscapulohumeral muscular dystrophy Raschâ€built overall disability scale (FSHDâ€RODS). European Journal of Neurology, 2021, 28, 2339-2348.	3.3	8
57	Randomized phase 2 study of <scp>ACE</scp>â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	2.2	8
58	Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI. Neurology, 2022, 99, .	1.1	8
59	Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. BMC Medical Research Methodology, 2018, 18, 19.	3.1	7
60	N-of-1 Trials in Neurology. Neurology, 2022, 98, .	1.1	7
61	FSHD1 or FSHD2: That is the question. Neurology, 2019, 92, 881-882.	1.1	6
62	A patientâ€focused survey to assess the effects of the <scp>COVID</scp>â€19 pandemic and social guidelines on people with muscular dystrophy. Muscle and Nerve, 2021, 64, 321-327.	2.2	6
63	A pilot study of the responsiveness of wireless motion analysis in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2019, 60, 590-594.	2.2	5
64	Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials. Statistics in Biopharmaceutical Research, 2019, 11, 375-386.	0.8	5
65	Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia. Brain Sciences, 2021, 11, 611.	2.3	5
66	Longâ€term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis. Muscle and Nerve, 2021, 64, 342-346.	2.2	5
67	Emerging Subspecialties in Neurology: Fellowship in experimental therapeutics of neurologic disease. Neurology, 2012, 79, e106-8.	1.1	4
68	Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets. Journal of Visualized Experiments, 2020, , .	0.3	4
69	Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 419-425.	1.7	4
70	Understanding the Perseverance of the Muscular Dystrophy Community One-Year into the COVID-19 Pandemic. Journal of Neuromuscular Diseases, 2022, 9, 517-523.	2.6	4
71	Achieving Life Milestones in Duchenne/Becker Muscular Dystrophy. Neurology: Clinical Practice, 2021, 11, 311-317.	1.6	3
72	Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64.	0.6	3

#	Article	IF	Citations
73	Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computerâ€assisted evaluation. Muscle and Nerve, 2022, 65, 560-567.	2.2	3
74	<scp>Nonâ€dystrophic</scp> myotonia: 2â€year clinical and patient reported outcomes. Muscle and Nerve, 2022, 66, 148-158.	2.2	3
75	A Roadmap to Patient Engagement. Neurology: Clinical Practice, 2021, 11, e722-e726.	1.6	1
76	N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, jnnp-2021-326347.	1.9	1
77	Demographics, clinical characteristics, and prognostic factors of amyotrophic lateral sclerosis in <scp>M</scp>idwest. Muscle and Nerve, 2022, 65, 217-224.	2.2	1
78	Openâ€label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	2.2	1
79	Quantitative Muscle Analysis in Facioscapulohumeral Muscular Dystrophy Using <scp>Wholeâ€Body Fatâ€Referenced MRI</scp> : Protocol Development, Multicenter Feasibility, and Repeatability. Muscle and Nerve, 2022, , .	2.2	1
80	Eyelid myotonia and face stiffness in skeletal muscle sodium channelopathy. RRNMF Neuromuscular Journal, 2021, 2, .	0.1	0
81	Night and day: Circadian rhythms and glucose tolerance. Science Translational Medicine, 2015, 7, .	12.4	0
82	Elucidating the role of C9orf72 mutations in ALS. Science Translational Medicine, 2015, 7, .	12.4	0
83	Measuring the cart before the horse: A new biomarker for Huntingtonâ€™s disease. Science Translational Medicine, 2015, 7, .	12.4	0
84	No longer aware of what cannot be remembered. Science Translational Medicine, 2015, 7, .	12.4	0
85	Out with the old (myelin), in with the new. Science Translational Medicine, 2015, 7, .	12.4	0
86	Stemming the tide of ALS. Science Translational Medicine, 2016, 8, .	12.4	0
87	Facioscapulohumeral muscular dystrophy. , 2020, , 511-523.		0
88	Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial. Kansas Journal of Medicine, 2020, 13, 10-13.	0.4	0
89	Reply: Wheelchair use in genetically-confirmed FSHD1 from a large cohort study in Chinese population. Brain, 2022, , .	7.6	0